Scientists at the University of Oxford, led by Professor Ahmed Ahmed, are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
In this study, the CRUK-funded researchers will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.
If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.
Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.
more recommended stories
T-bet and the Genetic Control of Memory B Cell DifferentiationIn a major advancement in immunology,.
Ultra-Processed Foods May Harm Brain Health in ChildrenUltra-Processed Foods Linked to Cognitive and.
Parkinson’s Disease Care Advances with Weekly InjectableA new weekly injectable formulation of.
Brain’s Biological Age Emerges as Key Health Risk IndicatorClinical Significance of Brain Age in.
Children’s Health in the United States is Declining!Summary: A comprehensive analysis of U.S..
Autoimmune Disorders: ADA2 as a Therapeutic TargetAdenosine deaminase 2 (ADA2) has emerged.
Is Prediabetes Reversible through Exercise?150 Minutes of Weekly Exercise May.
New Blood Cancer Model Unveils Drug ResistanceNew Lab Model Reveals Gene Mutation.
Healthy Habits Slash Diverticulitis Risk in Half: Clinical InsightsHealthy Habits Slash Diverticulitis Risk in.
Caffeine and SIDS: A New Prevention TheoryFor the first time in decades,.
Leave a Comment